Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? (Q37800934)

23 August 2017

Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow? (English)

1 reference

23 August 2017

1 reference

1 reference

Michael R Shurin

1

1 reference

23 August 2017

Melissa Gregory

series ordinal

2

1 reference

23 August 2017

John C Morris

series ordinal

3

1 reference

23 August 2017

Anatoli M Malyguine

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

Expert Opinion on Biological Therapy

23 August 2017

1 reference

23 August 2017

10

1 reference

23 August 2017

11

1 reference

23 August 2017

1539-1553

1 reference

Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype.

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

21 January 2018

DC-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Dendritic cell-based cancer gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Cytokine gene-mediated immunotherapy: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Genetically modified dendritic cells for therapeutic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Genetically modified dendritic cells for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivity to tumor-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Clinical considerations in developing dendritic cell vaccine based immunotherapy protocols in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Taming cancer by inducing immunity via dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Synergistic anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus intra-tumor injection of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Tumour immunity: effector response to tumour and role of the microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Bevacizumab--current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Intratumoural administration of dendritic cells: hostile environment and help by gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Immunotherapeutic strategies employing RNA interference technology for the control of cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Role of natural killer cell function in dendritic cell-based vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.526105

10.1517/14712598.2010.526105

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference